Laboratory of Neuroscience, Hospital Sírio-Libanês, São Paulo 01308-060, SP, Brazil.
Division of Functional Neurosurgery, Department of Neurology, University of Sao Paulo Medical School, São Paulo 05402-000, SP, Brazil.
Int J Mol Sci. 2023 Apr 25;24(9):7796. doi: 10.3390/ijms24097796.
Epidural motor cortex stimulation (MCS) is an effective treatment for refractory neuropathic pain; however, some individuals are unresponsive. In this study, we correlated the effectiveness of MCS and refractoriness with the expression of cytokines, neurotrophins, and nociceptive mediators in the dorsal root ganglion (DRG), sciatic nerve, and plasma of rats with sciatic neuropathy. MCS inhibited hyperalgesia and allodynia in two-thirds of the animals (responsive group), and one-third did not respond (refractory group). Chronic constriction injury (CCI) increased IL-1β in the nerve and DRG, inhibited IL-4, IL-10, and IL-17A in the nerve, decreased β-endorphin, and enhanced substance P in the plasma, compared to the control. Responsive animals showed decreased NGF and increased IL-6 in the nerve, accompanied by restoration of local IL-10 and IL-17A and systemic β-endorphin. Refractory animals showed increased TNF-α and decreased IFNγ in the nerve, along with decreased TNF-α and IL-17A in the DRG, maintaining low levels of systemic β-endorphin. Our findings suggest that the effectiveness of MCS depends on local control of inflammatory and neurotrophic changes, accompanied by recovery of the opioidergic system observed in neuropathic conditions. So, understanding the refractoriness to MCS may guide an improvement in the efficacy of the technique, thus benefiting patients with persistent neuropathic pain.
硬膜外运动皮层刺激(MCS)是治疗难治性神经性疼痛的有效方法;然而,有些人对此没有反应。在这项研究中,我们将 MCS 的有效性和难治性与大鼠背根神经节(DRG)、坐骨神经和血浆中细胞因子、神经营养因子和痛觉介质的表达相关联,这些大鼠患有坐骨神经病变。MCS 抑制了三分之二动物(反应组)的痛觉过敏和感觉异常,而三分之一动物没有反应(难治组)。与对照组相比,慢性缩窄性损伤(CCI)增加了神经和 DRG 中的 IL-1β,抑制了神经中的 IL-4、IL-10 和 IL-17A,降低了β-内啡肽,并增加了血浆中的 P 物质。反应性动物表现为神经中的 NGF 减少和 IL-6 增加,伴有局部 IL-10 和 IL-17A 以及全身β-内啡肽的恢复。难治性动物表现为神经中的 TNF-α 增加和 IFNγ 减少,同时 DRG 中的 TNF-α 和 IL-17A 减少,维持着低水平的全身β-内啡肽。我们的研究结果表明,MCS 的有效性取决于局部对炎症和神经营养变化的控制,同时伴有在神经病变情况下观察到的阿片能系统的恢复。因此,了解对 MCS 的难治性可能有助于提高该技术的疗效,从而使持续性神经性疼痛的患者受益。